Cynata Announces First Clinical Study Utilizing MSCs Manufactured by Cymerus™ Platform
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today by announcing that mesenchymal stem cells produced using its Cymerus™ manufacturing platform will be utilized in a Phase 1 clinical study involving patients with steroid-refractory GvHD.
The Clinical Trial Company Ltd was identified as the contract research organization (CRO) that Cynata has engaged to conduct the study.
CYP-001 is the lead mesenchymal stem cell (MSC) product manufactured using Cynata’s unique Cymerus™ technology, a platform which allows MSCs to be produced from a single donation given by an individual donor. The Cymerus™ technology creates induced pluripotent stem cell (iPSC) derived MSCs, solving a key issue now limiting the therapeutic use of MSC – the ability to produce consistent, scalable MSCs for clinical-grade use.
MSCs have shown promising results in the treatment of GvHD, as MSCs are modulatory cells that can alter a recipient’s immune response and reduce inflammation. Furthermore, MSCs are currently being explored in nearly 500 clinical trials worldwide, so their therapeutic potential is well-vetted. However, robust technologies for scaling and standardizing the manufacture of MSCs are scare.
Cynata Therapeutics is a promising stock for regenerative medicine investors to watch, because the company’s ability to produce consistent, scalable MSCs for clinical-grade use will substantially expand therapeutic applications for the cell type.
While Cynata Therapeutics is an Australian-based company, it was founded on technology developed at the University of Wisconsin, an institution known for the work of Dr. James Thomson, whose team first isolated human embryonic stem cells (hESCs) in 1998 and derived induced pluripotent stem cells (iPSCs) from adult human cells in 2007.
The company has also established global partnerships, aligning itself with Harvard University to test toxin-secreting stem cells for the treatment of cancer and the University of Sydney to test the potential therapeutic efficacy of Cymerus™ MSCs in animal models of myocardial infarction.
If you found this blog valuable, subscribe to BioInformant’s stem cell industry updates.